Literature DB >> 23230258

Phenytoin-induced Lyell's syndrome.

Bárbara Lobão1, Claúdio Martins, Manuel Sousa, Susana Marques, Ermelinda Pedroso.   

Abstract

Lyell's syndrome or toxic epidermal necrolysis (TEN) is a rare dermatological disease that causes serious morbidity and mortality. It is most commonly drug induced. The authors report the case of a 57-year-old woman who was admitted to our hospital with severe rash all over the body. She had been previously submitted to brain surgery for total resection of a large meningioma and medicated with phenytoin for seizures prophylaxis. During this treatment, erythematous lesions and blisters were observed first on her face and trunk and then spreading to the entire body. Detachment of the skin, as well as mucous involvement especially of mouth and conjunctiva, was also observed. TEN was diagnosed, and phenytoin was discontinued. Intravenous fluids, systemic steroids and tightened infection control measures were implemented. After 10 days, skin recovery and re-epithelialisation were established, temperature decreased and mucosal complications stabilised. The patient was discharged after 1 month of hospitalisation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23230258      PMCID: PMC4544985          DOI: 10.1136/bcr-2012-007746

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Toxic epidermal necrolysis: an eruption resembling scalding of the skin.

Authors:  A LYELL
Journal:  Br J Dermatol       Date:  1956-11       Impact factor: 9.302

2.  Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome.

Authors:  Riichiro Abe; Naoya Yoshioka; Junko Murata; Yasuyuki Fujita; Hiroshi Shimizu
Journal:  Ann Intern Med       Date:  2009-10-06       Impact factor: 25.391

3.  Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gamma-treated cultured keratinocytes.

Authors:  H Matsue; H Kobayashi; T Hosokawa; T Akitaya; A Ohkawara
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 4.  Toxic epidermal necrolysis.

Authors:  D S Becker
Journal:  Lancet       Date:  1998-05-09       Impact factor: 79.321

5.  Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions.

Authors:  Isabelle Viard-Leveugle; Roberto R Bullani; Paolo Meda; Olivier Micheau; Alain Limat; Jean-Hilaire Saurat; Jürg Tschopp; Lars E French
Journal:  J Biol Chem       Date:  2002-12-07       Impact factor: 5.157

6.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.

Authors:  B Rzany; O Correia; J P Kelly; L Naldi; A Auquier; R Stern
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

7.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.

Authors:  Maja Mockenhaupt; John Messenheimer; Pat Tennis; Juergen Schlingmann
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

Review 8.  [Toxic epidermal necrolysis (syndrome Lyell) versus Stevens-Johnson syndrome].

Authors:  B Jezierska-Krupa; L Hyla-Klekot
Journal:  Pediatr Pol       Date:  1996-07

Review 9.  [Stevens-Johnson syndrome, toxic epidermal necrolysis and phenytoin. Factors linked to a higher risk].

Authors:  M S Gómez-Criado; I Ayani; T León-Colombo; M L Ramos; M J Reneses
Journal:  Rev Neurol       Date:  2004 Jun 1-15       Impact factor: 0.870

10.  Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study.

Authors:  F Lebargy; P Wolkenstein; M Gisselbrecht; F Lange; J Fleury-Feith; C Delclaux; E Roupie; J Revuz; J C Roujeau
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.